He Shao-Heng, He Yong-Song, Xie Hua
Allergy and Inflammation Research Institute, Shantou University Medical College, Shantou 515031, Guangdong Province, China.
World J Gastroenterol. 2004 Feb 1;10(3):327-31. doi: 10.3748/wjg.v10.i3.327.
To investigate the ability of agonists of PAR-2 to stimulate release of tryptase and histamine from human colon mast cells and the potential mechanisms.
Enzymatically dispersed cells from human colons were challenged with tc-LIGRLO, tc-OLRGIL, SLIGKV, VKGILS, trypsin, anti-IgE or calcium ionophore A23187, and the cell supernatants after challenge were collected. Tryptase release was determined with a sandwich ELISA procedure and histamine release was measured using a glass fibre-based fluorometric assay.
Both PAR-2 agonists tc-LIGRLO-NH2 and SLIGKV-NH2 were able to induce dose dependent release of tryptase and histamine from colon mast cells. More than 2.5 fold increase in both tryptase and histamine release was provoked by 100 micromol/mL tc-LIGRLO-NH2, in comparison with only 2.0 fold increase being stimulated by SLIGKV-NH2. The reverse peptides tc-OLRGIL-NH2 and VKGILS -NH2 at the concentrations tested had no effect on the release of these two mediators. The maximum tryptase release elicited by tc-LIGRLO-NH2 was similar to that induced by anti-IgE (10 microg/mL) or calcium ionophore (1 microg/mL), though the latter was a more potent stimulus for histamine release. Both histamine and tryptase release in response to tc-LIGRLO-NH2 were completed within 3 min. Trypsin at concentrations from 1.0 to 100 microg/mL was capable of provoking a dose dependent release of tryptase as well as histamine with a maximum of 16 ng/mL tryptase and 14 ng/mL histamine release being achieved. An approximately 80% and 70% inhibition of trypsin induced release of tryptase and histamine were observed with SBTI, respectively. Pretreatment of cells with metabolic inhibitors or pertussis toxin abolished the actions of tc-LIGRLO-NH2, SLIGKV-NH2 and trypsin.
The agonists of PAR-2 and trypsin are potent secretagogues of human colon mast cells, which are likely to contribute to the development of inflammatory disorders in human gut.
研究蛋白酶激活受体-2(PAR-2)激动剂刺激人结肠肥大细胞释放类胰蛋白酶和组胺的能力及其潜在机制。
用tc-LIGRLO、tc-OLRGIL、SLIGKV、VKGILS、胰蛋白酶、抗IgE或钙离子载体A23187刺激经酶分散的人结肠细胞,收集刺激后的细胞上清液。用夹心酶联免疫吸附测定法测定类胰蛋白酶释放,用基于玻璃纤维的荧光测定法测量组胺释放。
PAR-2激动剂tc-LIGRLO-NH2和SLIGKV-NH2均能诱导结肠肥大细胞剂量依赖性释放类胰蛋白酶和组胺。100μmol/mL的tc-LIGRLO-NH2可使类胰蛋白酶和组胺释放增加2.5倍以上,而SLIGKV-NH2仅能刺激其增加2.0倍。在测试浓度下,反向肽tc-OLRGIL-NH2和VKGILS-NH2对这两种介质的释放无影响。tc-LIGRLO-NH2诱导的类胰蛋白酶最大释放量与抗IgE(10μg/mL)或钙离子载体(1μg/mL)诱导的相似,尽管后者对组胺释放的刺激作用更强。对tc-LIGRLO-NH2的组胺和类胰蛋白酶释放反应均在3分钟内完成。浓度为1.0至100μg/mL的胰蛋白酶能够引起类胰蛋白酶和组胺的剂量依赖性释放,类胰蛋白酶最大释放量为16ng/mL,组胺最大释放量为14ng/mL。大豆胰蛋白酶抑制剂(SBTI)分别使胰蛋白酶诱导的类胰蛋白酶和组胺释放抑制约80%和70%。用代谢抑制剂或百日咳毒素预处理细胞可消除tc-LIGRLO-NH2、SLIGKV-NH2和胰蛋白酶的作用。
PAR-2激动剂和胰蛋白酶是人结肠肥大细胞的强效促分泌剂,可能在人类肠道炎症性疾病的发生发展中起作用。